Abstract:There is a critical need to identify new therapeutic targets and treatments, given emerging data documenting the limited effectiveness of current antihypertensive drugs to have a marked impact in preventing target organ damage and cardiovascular death. While monoclonal antibodies (mAb) are revolutionizing the treatment of human diseases, including severe hypercholesterolemia, their applicability to long-term hypertension control remains unexplored. Identification of angiotensin-(1-12) [Ang-(1–12)] as a non-renin-dependent substrate for Ang II generation in rodents and humans led us to engineer a mAb directed against the C-terminus of human Ang-(1–12) [h-Ang-(1-12)] sequence. We utilized a model of hypertension expressing the human angiotensinogen (AGT) gene in the rat genome [TGR(hAGT)L1623 rats] to address the effectiveness of endogenous h-Ang-(1–12) immunoneutralization in controlling the elevated blood pressure and reversing hypertension-induced target organ damage. Acute delivery of the h-Ang-(1–12) mAb (30 mg/Kg, i.v.) in anesthetized hypertensive transgenic rats induced a prompt arterial pressure fall (M ± SE: -18 ± 6/-16 ± 3 mm Hg, n=7; p< 0.001) in the absence of corresponding heart rate changes. The antihypertensive effect of the h-Ang-(1-12) mAb triggered a rise in plasma renin concentrations (from 107 ± 24 to 381 ± 260 ng/mL/h) that was inversely correlated with the fall in mean arterial pressure (r= -0.92, p< 0.001). Prior intravenous delivery of aliskiren fumarate (3-5 mg/Kg, i.v.) while inducing a fall in arterial pressure did not mask the antihypertensive action of the h-Ang-(1-12) mAb. Extension of these acute effects of the h-Ang-(1-12) mAb to awake instrumented transgenic hypertensive rats given consecutive daily doses of the mAb (30 mg/Kg, i.m. x 4 -5 days, n=7) documented a trend for significant statistical drops in daytime blood pressure and no changes in heart rate. We conclude that Ang-(1–12) is an endogenous Ang II forming substrate participating in the control of arterial pressure in a humanized model of high blood pressure and that selective immunoneutralization of this alternate substrate is a promising and novel therapeutic approach to treat hypertension and prevent its adverse cardiovascular sequelae.

The Construction and Pharmacodynamic Action of a Novel Anti-renal Hypertension DNA Vaccine Targeted Angiotnensin Ⅱ

Construction and DNA Immunization of Human Renalase Eukaryotic Expression Vector

Combined vaccines against angiotensin II receptor type 1 and alpha 1D-adrenergic receptor for hypertension

Chronic Reduction in Paraventricular Nucleus (PVN) AT1R Expression by AAV‐mediated Transfer of a Small Hairpin RNA (shrna) Produces a Decrease in Blood Pressure in Spontaneously Hypertensive Rats

A novel vaccine targeting β1-adrenergic receptor

Construction and Evaluation of DNA Vaccine Encoding Hantavirus Glycoprotein N-terminal Fused with Lysosome-Associated Membrane Protein.

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Abstract 124: Angiotensin-(1-12) Immunoneutralization: A New Approach To Hypertension Treatment

The construction of a DNAvaccine targeting extracellular region of PDGF-R-2β gene

Dna Vaccination With Ccl2 Dna Modified By The Addition Of An Adjuvant Epitope Protects Against "Nonimmune" Toxic Renal Injury

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection

Variation of Serum Angiopoietin-2 in Renovascular Hypertensive Rats and Therapeutic Effect of Telmisartan

Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats

A renal-targeted gene delivery system derived from spermidine for arginase-2 silencing and synergistic attenuation of drug-induced acute kidney injury

Preventive effects of vasohibin-2-targeting peptide vaccine for diabetic nephropathy

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Danhong Injection Protects Against Hypertension-Induced Renal Injury Via Down-Regulation of Myoglobin Expression in Spontaneously Hypertensive Rats

Prevention of Angiotensin II-induced Hypertension and Cardiac Remodeling by Recombinant Human Angiotensin-Converting Enzyme 2 in Mice

Safety Evaluation of the DNA Vaccine Against Atherosclerosis in Mice and Rabbits

Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models

EFFECT OF LOSARTAN ON PRODUCE OF SERA AUTO-ANTIBODIES TO ANGIOTENSIN II-1 RECEPTORIN RENOVASCULAR HYPERTENSION RATS